BARD1 Life Sciences
Nedlands
About BARD1 Life Sciences
BARD1 Life Sciences (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. Additional diagnostic projects are being evaluated for prostate, breast and other cancers. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $18.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jul 2021)
- Ticker: asx:BD1
- Website: bard1.com
- Phone: +61 8 9381 9550
Industries & Categories
Biotechnology, Health Diagnostics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/bard1-life-sciences-99756 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.